Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma
被引:13
|
作者:
Benson, Don M., Jr.
论文数: 0引用数: 0
h-index: 0
机构:
Ohio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA
Ohio State Univ, Blood & Marrow Transplant Program, Columbus, OH 43210 USA
Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA
Ohio State Univ, Arthur G James Canc Hosp & Solove Res Inst, Columbus, OH 43210 USA
Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USAOhio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA
Benson, Don M., Jr.
[1
,2
,3
,4
,5
]
Panzner, Kathryn
论文数: 0引用数: 0
h-index: 0
机构:
Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USAOhio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA
Panzner, Kathryn
[3
]
论文数: 引用数:
h-index:
机构:
Hamadani, Mehdi
[1
]
Hofmeister, Craig C.
论文数: 0引用数: 0
h-index: 0
机构:
Ohio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA
Ohio State Univ, Blood & Marrow Transplant Program, Columbus, OH 43210 USA
Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA
Ohio State Univ, Arthur G James Canc Hosp & Solove Res Inst, Columbus, OH 43210 USA
Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USAOhio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA
Hofmeister, Craig C.
[1
,2
,3
,4
,5
]
Bakan, Courtney E.
论文数: 0引用数: 0
h-index: 0
机构:
Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USAOhio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA
Bakan, Courtney E.
[5
]
Smith, Megan K.
论文数: 0引用数: 0
h-index: 0
机构:
Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USAOhio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA
Smith, Megan K.
[5
]
Elder, Pat
论文数: 0引用数: 0
h-index: 0
机构:
Ohio State Univ, Blood & Marrow Transplant Program, Columbus, OH 43210 USA
Ohio State Univ, Arthur G James Canc Hosp & Solove Res Inst, Columbus, OH 43210 USAOhio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA
Elder, Pat
[2
,4
]
Krugh, David
论文数: 0引用数: 0
h-index: 0
机构:
Ohio State Univ, Blood & Marrow Transplant Program, Columbus, OH 43210 USA
Ohio State Univ, Arthur G James Canc Hosp & Solove Res Inst, Columbus, OH 43210 USAOhio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA
Krugh, David
[2
,4
]
论文数: 引用数:
h-index:
机构:
O'Donnell, Lynn
[2
,4
]
Devine, Steven M.
论文数: 0引用数: 0
h-index: 0
机构:
Ohio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA
Ohio State Univ, Blood & Marrow Transplant Program, Columbus, OH 43210 USA
Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA
Ohio State Univ, Arthur G James Canc Hosp & Solove Res Inst, Columbus, OH 43210 USA
Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USAOhio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA
Devine, Steven M.
[1
,2
,3
,4
,5
]
机构:
[1] Ohio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA
[2] Ohio State Univ, Blood & Marrow Transplant Program, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA
[4] Ohio State Univ, Arthur G James Canc Hosp & Solove Res Inst, Columbus, OH 43210 USA
[5] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
Multiple myeloma (MM) is the top indication for high-dose chemotherapy (HDC) with autologous stem cell transplantation (SCT), a strategy which improves progression-free survival and potentially overall survival (OS). Novel induction regimens incorporating the immunomodulatory (IMID) agents, such as thalidomide and lenalidomide and the proteosome inhibitor bortezomib improve response rates and survival for newly diagnosed patients. Recent data temper enthusiasm for these treatments by illustrating difficulty in some circumstances with mobilizing CD34(+) hematopoietic stem cells for subsequent HDC/SCT. We compare conventional induction regimens with novel agent-based induction strategies and the associated effects on stem cell mobilization and HDC/SCT outcome in 224 patients. Although patients exposed to novel agent inductions collected generally fewer CD34(+) cells than patients induced with chemotherapy, these differences did not translate into adverse consequences with subsequent HDC/SCT. We show that an improvement in OS after HDC/SCT may be related to induction therapy with novel agents as opposed to chemotherapy. Our data extrapolate on prior work and expand on ongoing controversies about optimal induction regimens for patients with MM planned for subsequent HDC/SCT and optimal sequencing of therapies.
机构:
Royal Adelaide Hosp, Haematol, Adelaide, SA, Australia
SA Pathol, Haematol, Adelaide, SA, AustraliaRoyal Adelaide Hosp, Haematol, Adelaide, SA, Australia